EUVIMEDEUVIMED entdecken
Klinische StudieMultizentrische StudieOpen Access

Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB Signaling

Rose C Velasco, Connie Shao, Brett Cutler, Jennifer Strunck, Gail Kent, Pamela B Cassidy, Keith Choate, Teri M Greiling

JAMA Dermatology · 2024

DOI: 10.1001/jamadermatol.2024.0257 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift JAMA Dermatology, 2024. Verfasst von Rose C Velasco und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Oregon Health & Science University, Portland. Hauptthemen laut MEDLINE: Pityriasis Rubra Pilaris, Antibodies, Monoclonal, Humanized, Interleukin-17, Signal Transduction. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance There is no US Food and Drug Administration–approved treatment for pityriasis rubra pilaris (PRP), and it is common for patients to fail to experience improvement with several systemic options. Involvement of interleukin (IL) 23 suggests a potential therapeutic target.

Objective

To determine whether guselkumab, an IL-23p19 inhibitor, provides clinical improvement for participants with PRP and better understand gene and protein dysregulation in PRP. Design, Setting, and Participants This single-arm, investigator-initiated nonrandomized trial was conducted from October 2019 to August 2022 at a single-center academic university with participants from 8 states in the US. In total, 14 adults with moderate to severe PRP were enrolled; 12 completed the trial. Age-matched and sex-matched healthy controls provided skin and blood for proteomic and transcriptomic studies. The primary outcome was observed at 24 weeks, and additional follow-up occurred at 36 weeks.

Intervention

Guselkumab is a fully human immunoglobulin G1 λ monoclonal antibody that selectively binds and inhibits the p19 subunit of IL-23. Subcutaneous injections were given at the US Food and Drug Administration–approved dosing schedule for psoriasis over a 24-week period. Main Outcomes and Measures The primary outcome was the mean change in the Psoriasis Area Severity Index (PASI) score at week 24. Secondary outcomes included pruritus, Dermatology Life Quality Index score, clinical response at week 36, and association with transcriptomics and proteomics expression.

Results

A per-protocol analysis was performed for the cohort of 4 female and 8 male patients who had a mean (SD) age of 56.5 (18.7) years. The mean improvement in PASI score, pruritus, and Dermatology Life Quality Index score was 61.8% ( P < .001), 62.3% ( P = .001), and 60.2% ( P < .001), respectively. Nine participants (75%) achieved a 50% improvement in PASI. Among these clinical responders, at week 36, 8 of 9 achieved PASI75, and 6 of 9 achieved PASI90. No participants had pathogenic CARD14 gene variations. There was 1 serious adverse event that was not associated with the study drug. Proteomics and gene expression profiles identified dysregulation of a predominance of inflammatory pathways (such as T helper 17 and nuclear factor κ B) in participants with PRP who later responded well to treatment with guselkumab and stronger dysregulation of keratinocyte development pathways in individuals who did not respond to guselkumab. Conclusion and Relevance The results of this nonrandomized trial suggest that guselkumab has efficacy in treating refractory moderate to severe adult PRP. Trial Registration ClinicalTrials.gov Identifier: NCT03975153

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pityriasis Rubra PilarisAntibodies, Monoclonal, HumanizedInterleukin-17Signal TransductionHumansMaleFemaleMiddle AgedAdultSeverity of Illness IndexInterleukin-23Treatment OutcomeInterleukin-23 Subunit p19AgedInjections, SubcutaneousGuanylate CyclaseMembrane ProteinsCARD Signaling Adaptor Proteins

Substanzen

guselkumabAntibodies, Monoclonal, HumanizedInterleukin-17Interleukin-23Interleukin-23 Subunit p19Guanylate CyclaseCARD14 protein, humanMembrane ProteinsCARD Signaling Adaptor Proteins

Autor:innen und Institutionen

  • Department of Dermatology, Oregon Health & Science University, Portland.
  • Department of Dermatology, Yale University, New Haven, Connecticut.

Förderung

  • NCATS NIH HHS

Zitieren

APA

Velasco, R. C., Shao, C., Cutler, B., Strunck, J., Kent, G., Cassidy, P. B., Choate, K., & Greiling, T. M. (2024). Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB Signaling. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2024.0257

Vancouver

Velasco RC, Shao C, Cutler B, Strunck J, Kent G, Cassidy PB, et al. Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB Signaling. JAMA Dermatology. 2024. doi:10.1001/jamadermatol.2024.0257

BibTeX
@article{Velasco2024,
  author = {Velasco, Rose C and Shao, Connie and Cutler, Brett and Strunck, Jennifer and Kent, Gail and Cassidy, Pamela B and Choate, Keith and Greiling, Teri M},
  title = {Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB Signaling},
  journal = {JAMA Dermatology},
  year = {2024},
  doi = {10.1001/jamadermatol.2024.0257}
}
Kostenlos starten →